Younger children are more responsive to amblyopia treatment

Article

Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years.

Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years, according to a study featured in Archives of Ophthalmology.

Dr Jonathon M. Holmes and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, performed a meta-analysis of 4 recently completed randomized amblyopia treatment. This was done to evaluate the correlation between age and improvement in logMAR amblyopic eye visual acuity.

Each analysis was adjusted for spherical equivalent refractive error in the affected eye, type of amblyopia, baseline amblyopic eye visual acuity, previous amblyopia treatment, study treatment and protocol.

The results demonstrated that children aged between 7 and 13 years had a significantly reduced response rate to amblyopia treatment than children less than 7 years of age. However, no differences were found between those aged 3 to 5 years and those aged between 5 and 7 years with moderate ambylopia. Children aged between 3 to 5 years with severe ambylopia had a greater response to treatment than those aged 5 to 7 years.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.